Ignite Creation Date:
2025-12-25 @ 3:30 AM
Ignite Modification Date:
2025-12-26 @ 2:11 AM
Study NCT ID:
NCT04861805
Status:
RECRUITING
Last Update Posted:
2025-06-29
First Post:
2021-04-20
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Pivotal Study of the Vienna Transcatheter Self Expandable Aortic Valve SE System
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D006331', 'term': 'Heart Diseases'}], 'ancestors': [{'id': 'D002318', 'term': 'Cardiovascular Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'OTHER', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'This is a prospective, single arm, multicenter pivotal study in an expanding cohort of symptomatic patients with severe aortic stenosis (following the initial FIH feasibility study).'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 267}}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2023-07-03', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-06', 'completionDateStruct': {'date': '2030-10', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-06-25', 'studyFirstSubmitDate': '2021-04-20', 'studyFirstSubmitQcDate': '2021-04-22', 'lastUpdatePostDateStruct': {'date': '2025-06-29', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2021-04-27', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-10', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'All Cause Mortality (30 days)', 'timeFrame': 'up to 30 days', 'description': 'All-cause mortality at 30 days from the index procedure.'}], 'secondaryOutcomes': [{'measure': 'All-cause, cardiovascular and non-cardiovascular mortality', 'timeFrame': 'up to 5 years', 'description': 'All-cause, cardiovascular and non-cardiovascular mortality at 30 days, 3 months, 6 months, 1 year and every year thereafter up to 5 years post-implantation.'}, {'measure': 'Periprocedural death', 'timeFrame': '72 hours', 'description': 'Incidence of peri-procedural death (to capture intra-procedural events that result in immediate or consequent death ≤72 h post-procedure)'}, {'measure': 'Incidence of TAVI-related complications', 'timeFrame': 'periprocedural and during index hospitalization', 'description': 'Incidence of TAVI-related complications:\n\n1. Valve-related complication requiring repeat procedure\n2. Vascular complications resulting in interventions\n3. Ventricular septal perforation ≤7 days after IMD implantation\n4. Acute kidney injury-Stage 2 or 3 ≤7 days post IMD implantation\n5. Coronary artery obstruction requiring intervention\n6. Atrio-ventricular block requiring pacemaker implantation\n7. Mitral valve apparatus damage or dysfunction\n8. Evidence of a new pericardial effusion/ tamponade related to the TAVI procedure\n9. Prosthetic valve endocarditis\n10. Prosthetic valve thrombosis\n11. Prosthetic valve mispositioning\n12. Prosthetic valve embolization\n13. Valve-related dysfunction (mean aortic valve gradient ≥20 mmHg, EOA ≤0.9-1.1 cm2 and/or DVI peak velocity \\>0.35 m/s, AND/OR moderate or severe prosthetic valve regurgitation)'}, {'measure': 'Cerebrovascular event', 'timeFrame': 'Up to 5 years', 'description': 'Cerebrovascular event (at 30 days, 3 months, 6 months, 1 year and every year thereafter up to 5 years post-implantation):\n\n1. Stroke, defined as an acute episode of focal or global neurological dysfunction caused by the brain, spinal cord, or retinal vascular injury as a result of haemorrhage or infarction\n2. Transient ischemic attack (TIA), defined as a transient episode of focal neurological dysfunction caused by the brain, spinal cord, or retinal ischemia, without acute infarction. The difference between TIA and ischemic stroke is the presence of tissue damage on neuro-imaging studies or new sensory-motor deficit persisting \\>24 h. By definition, a TIA does not produce a lasting disability.'}, {'measure': 'Life-threatening bleeding', 'timeFrame': 'Up to 1 year', 'description': 'Life-threatening bleeding (at 30 days, 3 months, 6 months and 1 year post-implantation).'}, {'measure': 'Conduction disturbances requiring permanent pacemaker implantation', 'timeFrame': 'Up to 5 years', 'description': 'Conduction disturbances requiring permanent pacemaker implantation (at 30 days, 3 months, 6 months, 1 year and every year thereafter up to 5 years post-implantation)'}, {'measure': 'Rehospitalization', 'timeFrame': 'Up to 5 years', 'description': 'Re-hospitalization for valve-related complications or worsening congestive heart failure (at 30 days, 3 months, 6 months, 1 year and every year thereafter up to 5 years post-implantation)'}, {'measure': 'Device Success', 'timeFrame': '72 hours', 'description': 'Device success defined as:\n\na. correct positioning of a single prosthetic investigational heart valve in the proper anatomical location AND ability to provide appropriate hemodynamic AND absence of peri-procedural mortality within 72 hours after implantation'}, {'measure': 'Technical success', 'timeFrame': 'up to 30 days', 'description': 'Technical success defined as\n\n1. successful vascular access, delivery and deployment of the IMD and successful retrieval of the delivery system; and\n2. correct positioning of a single prosthetic investigational heart valve in the proper anatomical location\n3. in patients alive at 30 days with implanted Vienna valve:\n\n 1. Total aortic regurgitation of none/trace/mild/mild-moderate\n 2. Patient prosthesis mismatch (PPM) insignificant\\*\n 3. Mean gradient \\< 20 mmHg'}, {'measure': 'Clinical Efficacy', 'timeFrame': '1 year', 'description': 'Clinical efficacy (at 1 year and thereafter)\n\n1. Freedom from all-cause mortality\n2. Freedom from all stroke\n3. Freedom from hospitalization for procedure- or valve-related causes\n4. Freedom from KCCQ Overall Summary Score \\<45 or decline from baseline of \\>10 point (i.e. Unfavourable Outcome)'}, {'measure': 'Valve-related clinical efficacy', 'timeFrame': 'Up to 5 years', 'description': 'Valve-related clinical efficacy\n\n1. Freedom from bioprosthetic Valve Failure (defined as: Valve-related mortality OR Aortic valve re-operation/re-intervention OR Stage 3 haemodynamic valve deterioration)\n2. Freedom from stroke or peripheral embolism (presumably valve-related, after ruling out other non-valve aetiologies)\n3. Freedom from VARC Type 2-4 bleeding secondary to or exacerbated by antiplatelet or anticoagulant agents, used specifically for valve-related concerns (e.g. clinically apparent leaflet thrombosis)'}, {'measure': 'New York Heart Association (NYHA) classification', 'timeFrame': 'Up to 5 years', 'description': 'Change in heart failure symptoms from baseline as assessed by the New York Heart Association (NYHA) classification (at 30 days, 3 months, 6 months, 1 year and every year thereafter up to 5 years post-implantation)'}, {'measure': 'Change in quality of life as assessed by the Kansas City Cardiomyopathy', 'timeFrame': '1 year', 'description': 'Scale from 0 to 100 and summarized in 25-point ranges, where scores represent health status as follows: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent'}, {'measure': 'Change in exercise capacity measured as the 6-minute walk distance (6-MWD)', 'timeFrame': '1 year', 'description': 'Change in exercise capacity from baseline measured as the 6-minute walk distance (6-MWD) (at 30 days, 3 months, 6 months and 1 year post-implantation)'}]}, 'oversightModule': {'isUsExport': False, 'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['heart disease', 'aortic valve', 'SSAS', 'symptomatic severe aortic stenosis', 'heart valve'], 'conditions': ['Symptomatic Aortic Stenosis']}, 'referencesModule': {'references': [{'pmid': '38591535', 'type': 'DERIVED', 'citation': 'Briedis K, Rumbinaite E, Aldujeli A, Briede K, Jurenas M, Jakuska P, Jankauskas A, Ceponiene I, Lenkutis T, Plisiene J, Benetis R, Zaliunas R. One-year initial efficacy and safety outcomes of the premounted dry-pericardium Vienna self-expandable transcatheter aortic valve system: A first-in-human VIVA feasibility study. Catheter Cardiovasc Interv. 2024 Jun;103(7):1111-1124. doi: 10.1002/ccd.31039. Epub 2024 Apr 9.'}, {'pmid': '37567022', 'type': 'DERIVED', 'citation': 'Briedis K, Aldujeli A, Zaliunas R, Benetis R. Early Safety and Performance of the Premounted Dry-Pericardium Vienna Self-Expandable Transcatheter Aortic Valve System: 30-Day Outcomes of the First-in-Human VIVA Feasibility Study. Am J Cardiol. 2023 Oct 1;204:302-311. doi: 10.1016/j.amjcard.2023.07.109. Epub 2023 Aug 9.'}, {'pmid': '37522086', 'type': 'DERIVED', 'citation': 'Briedis K, Mizariene V, Rumbinaite E, Jurenas M, Aldujeli A, Briede K, Jakuska P, Jankauskas A, Ceponiene I, Lenkutis T, Zaliunas R, Benetis R. Safety and performance of the Vienna self-expandable transcatheter aortic valve system: 6-month results of the VIVA first-in-human feasibility study. Front Cardiovasc Med. 2023 Jul 13;10:1199047. doi: 10.3389/fcvm.2023.1199047. eCollection 2023.'}], 'seeAlsoLinks': [{'url': 'https://productsandfeatures.com/', 'label': 'Products \\& Features, manufacturer of VIVA Transcatheter Aortic Valve System'}, {'url': 'http://meditrial.com', 'label': 'Meditrial Clinical Research Organization'}]}, 'descriptionModule': {'briefSummary': 'This is a prospective, single arm, multicenter study in an cohort of up to 267 patients (up to 100 Roll-ins and 167 patients implanted per protocol) symptomatic patients with severe aortic stenosis who will be followed up for up to 5 years.', 'detailedDescription': 'The purpose of this trial is to determine the safety and effectiveness of the Vienna Aortic Valve SE System, a new self-expanding transcatheter heart valve, in patients with symptomatic severe aortic stenosis (SSAS). This is a prospective, single arm, multicenter study in an expanding cohort of symptomatic patients with severe aortic stenosis following the FIH feasibility study. The clinical investigation comprises 11 visits (V1 to V11). After implantation of the IMD at visit 2, safety and effectiveness assessment of the device will be performed at 30 days (V4), 3 months (V5), 6 months (V6), 1 year (V7) and every year thereafter up to 5 years post-implantation (V8 to V11).\n\nIn summary, the clinical investigation for the individual patient will end after 5 years with a full clinical evaluation. The primary study endpoints for safety and effectiveness will be reached at 30-day follow-up timepoint.\n\nThe clinical trial is completed after all 267 patients, that are not prematurely withdrawn, have completed their 5-year follow-up visit involving all specified assessments.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['OLDER_ADULT'], 'minimumAge': '65 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion criteria:\n\n1. Male or Female\n2. Age ≥ 65 years at time of consent\n3. Women of non-childbearing potential\n4. Severe degenerative calcific native aortic valve stenosis with the following criteria assessed either by resting or dobutamine stress TTE:\n\n 1. Aortic valve area (AVA) \\< 1.0 cm2 or AVA index ≤ 0.6 cm2/m2 and\n 2. Jet velocity \\> 4.0 m/s or mean gradient \\> 40 mmHg\n5. Symptomatic aortic stenosis (AS), defined as a history of at least one of the following:\n\n 1. Dyspnea that qualifies at NYHA class II or greater\n 2. Angina pectoris\n 3. Cardiac syncope\n6. Subject is considered at intermediate or high risk for surgical valve replacement based on at least one of the following:\n\n 1. EuroSCORE II ≥ 4% along with assessment of frailty, major organ system dysfunction, and procedure-specific impediments, in accordance with scientific guidelines\n 2. Agreement by the Heart Team that subject is at moderate to high operative risk of serious morbidity or mortality with surgical valve replacement.\n7. The local Heart Team deems the patient to be eligible for transfemoral TAVI.\n8. Perimeter-based aortic annulus diameter between ≥ 18 and ≤ 29 mm measured by computed tomography (CT) analyzed by a core lab.\n9. Adequate iliofemoral access with either:\n\n 1. At least one side with minimum vessel diameter ≥ 6.0 mm and acceptable level of vessel calcification and tortuosity for safe placement of the introducer sheath, as analyzed by a core lab, OR\n 2. At least one side with minimum vessel diameter ≥ 5.5 and no significant calcification or severe tortuosity for safe placement of the introducer sheath, as analyzed by a core lab.\n10. Patient (or legal representative) understands the study requirements and the treatment procedures and provides written informed consent.\n11. The patient and the treating physician agree that the patient will return for all required post-procedure follow-up visits.\n\nExclusion Criteria:\n\nCardiovascular System:\n\n1. Patient has a congenital unicuspid or bicuspid aortic valve or non-calcified valves.\n2. Evidence of an acute myocardial infarction (MI) ≤ 30 days prior to screening or IMD implantation (defined as Q-wave MI or non-Q-wave MI with total CK elevation ≥ twice normal in the presence of CK-MB elevation and/or troponin elevation).\n3. Patient has had a cerebrovascular stroke or TIA within the past 90 days implantation prior to screening or valve implantation.\n4. Patient has a hypertrophic obstructive cardiomyopathy.\n5. History of any therapeutic invasive cardiac procedure (including balloon aortic valvuloplasty) within 30 days prior to screening or IMD implantation (except for pacemaker implantation which is allowed).\n6. Untreated clinically significant coronary artery disease requiring revascularization at the screening visit.\n7. Severe left ventricular dysfunction with left ventricular ejection fraction (LVEF) \\< 20% by echocardiography, contrast ventriculography, or radionuclide ventriculography.\n8. Patient with cardiogenic shock manifested by low cardiac output and hemodynamic instability and vasopressor dependence, or mechanical hemodynamic support\n9. Patients with clinically significant conduction abnormalities (clinically significant sinus bradycardia, sinus block or pauses, clinically significant atrioventricular (AV)-block \\>I) at screening and at time of IMD implantation.\n10. Patient has severe peripheral vascular disease:\n\n 1. including aortic aneurysm defined as maximal luminal diameter \\> 5 cm or with documented presence of thrombus, marked tortuosity, narrowing of the abdominal aorta, severe unfolding of the thoracic aorta or thick \\[\\> 5 mm\\], protruding or ulcerated atheroma in the aortic arch) or\n 2. symptomatic carotid or vertebral disease or successful treatment of carotid stenosis within 30 days prior to screening or IMD implantation.\n11. Patient with iliofemoral vessel characteristics that would preclude safe passage of the introducer (both sides), as analyzed by a core lab:\n\n 1. severe calcification,\n 2. severe tortuosity (\\> two 90-degree bends),\n 3. diameter \\< 6 mm, in patients with acceptable levels of calcification and acceptable levels of tortuosity\n 4. diameter \\< 5.5, in patients with no calcification and no significant tortuosity, OR\n 5. subject has had an aorto-femoral bypass\n12. Patient with active bacterial endocarditis within 6 months prior to screening or IMD implantation.\n13. Patient has (echocardiographic/ CT and/or MRI) evidence of intra-cardiac mass, thrombus or vegetation.\n14. Patient has a pre-existing prosthetic heart valve in any position (Note: mitral ring is not an exclusion).\n15. Patient has severe mitral regurgitation, severe aortic regurgitation or severe tricuspid regurgitation, moderate or severe mitral stenosis.\n16. Patient has a need for emergency surgery for any reason at time of screening or IMD implantation.\n\n General:\n17. Any condition considered a contraindication for placement of a bioprosthetic valve (e.g. patient with contraindication to oral antiplatelet therapy)\n18. Patient with renal insufficiency (eGFR \\< 30 ml/min per the Cockcroft-Gault formula) and/ or renal replacement therapy and/ or has serum creatinine level \\> 3.0 mg/dL or 265 µmol/L replacement therapy at the time of screening\n19. Patient with significant pulmonary disease (FEV1 \\< 30%) or currently on home oxygen\n20. Severe pulmonary hypertension (e.g., pulmonary artery systolic pressure ≥ 60 mmHg)\n21. Patients with evidence of an active systemic infection or sepsis.\n22. Patient has a known hypersensitivity or contraindication to contrast media, bovine tissue, nitinol (titanium or nickel), contraindication to oral antiplatelet therapy (aspirin, ticlopidine or clopidogrel) or heparin.\n23. Patient has a haemoglobin \\< 9 g/dL, platelet count \\< 50,000 cells/mm3 or \\> 700.000 cells/mm3, or white blood cell count \\< 1.000 cells/mm3, history of bleeding diathesis or coagulopathy\n24. Patient has peptic ulcer disease or history of gastrointestinal bleeding within the 3 months prior to screening or IMD implantation.\n25. Patient refuses blood transfusions.\n26. Patient has a life expectancy of less than 12 months due to non-cardiac, co-morbid conditions based on the assessment of the investigator at the time of enrolment (i.e. the time of informed consent).\n27. Patient is pregnant or breast feeding.\n28. Severe dementia (resulting in either inability to provide informed consent for the study/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits).\n29. Other medical, social, or psychological conditions that in the opinion of the Investigator precludes the patient from appropriate consent or adherence to the protocol required follow-up exams.\n30. Patient is currently participating in another investigational drug or device study that has not reached its primary endpoint (excluding observational studies).'}, 'identificationModule': {'nctId': 'NCT04861805', 'acronym': 'VIVA', 'briefTitle': 'Pivotal Study of the Vienna Transcatheter Self Expandable Aortic Valve SE System', 'organization': {'class': 'INDUSTRY', 'fullName': 'P+F Products + Features GmbH'}, 'officialTitle': 'A Two -Stage First in Human (FIH) Feasibility / Pivotal Study of the Vienna Aortic Valve SE System', 'orgStudyIdInfo': {'id': 'CTP-VIE-001'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'OTHER', 'label': 'Vienna Aortic Valve', 'description': 'transcatheter aortic valve implantation (TAVI)', 'interventionNames': ['Device: Vienna Aortic Valve SE System']}], 'interventions': [{'name': 'Vienna Aortic Valve SE System', 'type': 'DEVICE', 'description': 'Vienna Aortic Valve SE system for TAVI.', 'armGroupLabels': ['Vienna Aortic Valve']}]}, 'contactsLocationsModule': {'locations': [{'zip': 'B8000', 'city': 'Bahía Blanca', 'status': 'NOT_YET_RECRUITING', 'country': 'Argentina', 'contacts': [{'name': 'Alejandro Alvarez Iorio, MD', 'role': 'CONTACT', 'email': 'alexalv1970@gmail.com'}, {'name': 'Alejandro Alvarez Iorio, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital Privado Sur (FUMEBA)', 'geoPoint': {'lat': -38.7176, 'lon': -62.26545}}, {'zip': 'C1093', 'city': 'Buenos Aires', 'status': 'NOT_YET_RECRUITING', 'country': 'Argentina', 'contacts': [{'name': 'Oscar Mendiz, MD', 'role': 'CONTACT', 'email': 'omendiz@ffavaloro.org'}, {'name': 'Oscar Mendiz, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Fundación Favaloro', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': 'C1199ABB', 'city': 'Buenos Aires', 'status': 'NOT_YET_RECRUITING', 'country': 'Argentina', 'contacts': [{'name': 'Carla Agatiello, MD', 'role': 'CONTACT', 'email': 'carla.agatiello@hospitalitaliano.org.ar'}, {'name': 'Carla Agatiello, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital Italiano De Buenos Aires', 'geoPoint': {'lat': -34.61315, 'lon': -58.37723}}, {'zip': '22240-006', 'city': 'Rio de Janeiro', 'state': 'Rio de Janeiro', 'status': 'NOT_YET_RECRUITING', 'country': 'Brazil', 'contacts': [{'name': 'Cesar R Medeiros, MD', 'role': 'CONTACT', 'email': 'cr.medeiros@terra.com.br', 'phone': '+55 21 2285-3344'}, {'name': 'Cesar R Medeiros, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Instituto Nacional de Cardiologia', 'geoPoint': {'lat': -22.90642, 'lon': -43.18223}}, {'zip': '04023-062', 'city': 'São Paulo', 'state': 'São Paulo', 'status': 'NOT_YET_RECRUITING', 'country': 'Brazil', 'contacts': [{'name': 'Adriano M Caixeta, MD', 'role': 'CONTACT', 'email': 'adriano.caixeta@unifesp.br', 'phone': '+55 11 5576-4848'}, {'name': 'Adriano M Caixeta, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Escola Paulista de Medicina da UNIFESP', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': '22261-010', 'city': 'Rio de Janeiro', 'status': 'RECRUITING', 'country': 'Brazil', 'contacts': [{'name': 'Marcio Jose Montenegro Da Costa, MD', 'role': 'CONTACT', 'email': 'marciojmontenegro@gmail.com'}, {'name': 'Marcio Jose Montenegro Da Costa, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Instituto Estadual De Cardiologia Aloysio De Castro', 'geoPoint': {'lat': -22.90642, 'lon': -43.18223}}, {'zip': '04012-909', 'city': 'São Paulo', 'status': 'RECRUITING', 'country': 'Brazil', 'contacts': [{'name': 'Dimytri Siqueira, MD', 'role': 'CONTACT', 'email': 'dimytrisiqueira@gmail.com'}, {'name': 'Dimytri Siqueira, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Instituto Dante Pazzanese De Cardiologia', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': '05403-900', 'city': 'São Paulo', 'status': 'RECRUITING', 'country': 'Brazil', 'contacts': [{'name': 'Alexandre Abizaid, MD', 'role': 'CONTACT', 'email': 'aabizaid@uol.com.br'}, {'name': 'Alexandre Abizaid, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Instituto Do Coração (InCor) De São Paulo', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': '7500691', 'city': 'Santiago', 'status': 'RECRUITING', 'country': 'Chile', 'contacts': [{'name': 'Christian Dauvergne', 'role': 'CONTACT', 'email': 'cdauvergnem@yahoo.com'}, {'name': 'Christian Dauvergne, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital Del Torax De Santiago', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '8360160', 'city': 'Santiago', 'status': 'RECRUITING', 'country': 'Chile', 'contacts': [{'name': 'Gabriel Maluenda, MD', 'role': 'CONTACT', 'email': 'gabrielmaluenda@gmail.com', 'phone': '+56 2 2574 9000'}, {'name': 'Gabriel Maluenda, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital Clínico San Borja Arriarán', 'geoPoint': {'lat': -33.45694, 'lon': -70.64827}}, {'zip': '4270940', 'city': 'Talcahuano', 'status': 'RECRUITING', 'country': 'Chile', 'contacts': [{'name': 'Osvaldo Perez, MD', 'role': 'CONTACT', 'email': 'osperez2000@gmail.com'}, {'name': 'Osvaldo Perez, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital Las Higueras - Talcahuano', 'geoPoint': {'lat': -36.72494, 'lon': -73.11684}}, {'zip': '560099', 'city': 'Bangalore', 'status': 'NOT_YET_RECRUITING', 'country': 'India', 'contacts': [{'name': 'Sanjay Mehrotra, MD', 'role': 'CONTACT', 'email': 'info.nics@narayanahealth.org'}, {'name': 'Sanjay Mehrotra, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Narayana Health, Multispeciality Hospital', 'geoPoint': {'lat': 12.97194, 'lon': 77.59369}}, {'zip': '122001', 'city': 'Gurgaon', 'status': 'NOT_YET_RECRUITING', 'country': 'India', 'contacts': [{'name': 'Praveen Chandra, MD', 'role': 'CONTACT', 'email': 'pravenn.chandra@medanta.org', 'phone': '+91 124 414 1414'}, {'name': 'Praveen Chandra, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Medanta - The Medicity Multi-Speciality Hospital', 'geoPoint': {'lat': 25.49781, 'lon': 82.15916}}, {'zip': '302018', 'city': 'Jaipur', 'status': 'NOT_YET_RECRUITING', 'country': 'India', 'contacts': [{'name': 'Ravinder Singh Rao, MD', 'role': 'CONTACT', 'email': 'drravindersinghrao@yahoo.co.in', 'phone': '+91 141 272 0020'}, {'name': 'Ravinder Singh Rao, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'RHL- Rajasthan Hospital', 'geoPoint': {'lat': 26.91962, 'lon': 75.78781}}, {'zip': '682017', 'city': 'Kochi', 'status': 'NOT_YET_RECRUITING', 'country': 'India', 'contacts': [{'name': 'Rony Mathew Kadavil, MD', 'role': 'CONTACT', 'email': 'contact@lisiehospital.org', 'phone': '+91 484 240 2044'}, {'name': 'Rony Mathew Kadavil, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'LISIE Hospital', 'geoPoint': {'lat': 9.93988, 'lon': 76.26022}}, {'zip': '632 004', 'city': 'Vellore', 'status': 'NOT_YET_RECRUITING', 'country': 'India', 'contacts': [{'name': 'John Jose E, MD', 'role': 'CONTACT', 'email': 'drjohnjose@gmail.com', 'phone': '+91 8000338855'}, {'name': 'John Jose E, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Christian Medical College Hospital', 'geoPoint': {'lat': 12.9184, 'lon': 79.13255}}, {'zip': '50161', 'city': 'Kaunas', 'state': 'Kaunas County', 'status': 'RECRUITING', 'country': 'Lithuania', 'contacts': [{'name': 'Kasparas Briedis, Dr', 'role': 'CONTACT'}, {'name': 'Rimantas Benetis, Prof', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital of Lithuanian University of Health Sciences Kauno klinikos', 'geoPoint': {'lat': 54.90156, 'lon': 23.90909}}, {'zip': '1169-024', 'city': 'Lisbon', 'state': 'Lisbon District', 'status': 'RECRUITING', 'country': 'Portugal', 'contacts': [{'name': 'Duarte Cacela, MD', 'role': 'CONTACT', 'email': 'duarte.cacela@chlc.min-saude.pt', 'phone': '+351 21 359 4000'}, {'name': 'Duarte Cacela, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital Santa Marta', 'geoPoint': {'lat': 38.72509, 'lon': -9.1498}}, {'zip': '1649-028', 'city': 'Lisbon', 'state': 'Lisbon District', 'status': 'RECRUITING', 'country': 'Portugal', 'contacts': [{'name': 'Pedro C Ferreira, MD', 'role': 'CONTACT', 'email': 'pcarrilhoferreira@gmail.com', 'phone': '+351 21 780 5000'}, {'name': 'Pedro C Ferreira, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital Santa Maria', 'geoPoint': {'lat': 38.72509, 'lon': -9.1498}}, {'zip': '2790-134', 'city': 'Carnaxide', 'status': 'RECRUITING', 'country': 'Portugal', 'contacts': [{'name': 'João Brito, MD', 'role': 'CONTACT', 'email': 'jdbrito@chlo.min-saude.pt', 'phone': '+351 21 043 1000'}, {'name': 'João Brito, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital de Santa Cruz', 'geoPoint': {'lat': 38.72706, 'lon': -9.24671}}, {'zip': '4434-502', 'city': 'Vila Nova de Gaia', 'status': 'RECRUITING', 'country': 'Portugal', 'contacts': [{'name': 'Pedro Braga, MD', 'role': 'CONTACT', 'email': 'jplpbraga@gmail.com', 'phone': '+351 22 786 5100'}, {'name': 'Pedro Braga, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Unidade Local de Saúde de Gaia e Espinho', 'geoPoint': {'lat': 41.12401, 'lon': -8.61241}}, {'zip': '7000-811', 'city': 'Evora', 'state': 'Évora District', 'status': 'NOT_YET_RECRUITING', 'country': 'Portugal', 'contacts': [{'name': 'Lino MR Patrício, MD', 'role': 'CONTACT', 'email': 'linopatricio@gmail.com', 'phone': '+351 266 740 100'}, {'name': 'Lino MD Patrício, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital do Espírito Santo de Évora', 'geoPoint': {'lat': 38.56587, 'lon': -7.90405}}, {'zip': '08036', 'city': 'Barcelona', 'state': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Ander Regueiro, MD', 'role': 'CONTACT', 'email': 'aregueir@clinic.cat', 'phone': '+34 932 27 54 00'}, {'name': 'Ander Regueiro, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital Clinic De Barcelona', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '08041', 'city': 'Barcelona', 'state': 'Barcelona', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Lluis A Serra, MD', 'role': 'CONTACT', 'email': 'lasmarats@santpau.cat', 'phone': '+34 932 91 90 00'}, {'name': 'Lluis A Serra, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital de la Santa Creu i Sant Pau', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '28034', 'city': 'Madrid', 'state': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Ángel S Recalde, MD', 'role': 'CONTACT', 'email': 'asrecalde@hotmail.com', 'phone': '+34 913 36 80 00'}, {'name': 'Ángel S Recalde, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital Universitario Ramón y Cajal', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28040', 'city': 'Madrid', 'state': 'Madrid', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Luis Nombela, MD', 'role': 'CONTACT', 'email': 'luisnombela@yahoo.com', 'phone': '+34 913 30 30 00'}, {'name': 'Luis Nombela, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital Clinico San Carlos', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '47003', 'city': 'Valladolid', 'state': 'Valladolid', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Ignacio J Amat-Santos, MD', 'role': 'CONTACT', 'email': 'ijamat@gmail.com', 'phone': '+34 983 42 00 00'}, {'name': 'Ignacio J Amat-Santos, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'University Clinical Hospital of Valladolid', 'geoPoint': {'lat': 41.65541, 'lon': -4.72353}}, {'zip': '28222', 'city': 'Majadahonda', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Juan Oteo, MD', 'role': 'CONTACT', 'email': 'jf.oteo@gmail.com', 'phone': '+34 911 91 60 00'}, {'name': 'Juan Oteo, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital Puerta De Hierro', 'geoPoint': {'lat': 40.47353, 'lon': -3.87182}}, {'zip': '29010', 'city': 'Málaga', 'status': 'RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Juan Horacio A Briales, MD', 'role': 'CONTACT', 'email': 'juanhalonso62@gmail.com', 'phone': '+34 951 03 20 00'}, {'name': 'Juan Horacio A Briales, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital Virgen De La Victoria', 'geoPoint': {'lat': 36.72016, 'lon': -4.42034}}, {'zip': '33011', 'city': 'Oviedo', 'status': 'NOT_YET_RECRUITING', 'country': 'Spain', 'contacts': [{'name': 'Cesar Morís de La Tassa, MD', 'role': 'CONTACT', 'email': 'cesarmoris@gmail.com', 'phone': '+34 985 10 80 00'}, {'name': 'Cesar Morís de la Tassa, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Hospital Universitario Central de Asturias', 'geoPoint': {'lat': 43.36029, 'lon': -5.84476}}, {'zip': '34295', 'city': 'Istanbul', 'state': 'Istanbul', 'status': 'NOT_YET_RECRUITING', 'country': 'Turkey (Türkiye)', 'contacts': [{'name': 'Hakan Ucar, MD', 'role': 'CONTACT', 'email': 'ucarhakan2005@gmail.com', 'phone': '+90 4444484'}, {'name': 'Hakan Ucar, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'İ.A.Ü. VM Medical Park Florya Hospital', 'geoPoint': {'lat': 41.01384, 'lon': 28.94966}}], 'centralContacts': [{'name': 'Katharina Kiss, Dr', 'role': 'CONTACT', 'email': 'kkiss@productsandfeatures.com', 'phone': '+4369913289414'}, {'name': 'Monica Tocchi, MD, PhD', 'role': 'CONTACT', 'email': 'm.tocchi@meditrial.net', 'phone': '9176841700'}], 'overallOfficials': [{'name': 'Alexandre Abizaid, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Instituto do Coração (InCor) de São Paulo'}, {'name': 'Carla Agatiello, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital Italiano de Buenos Aires'}, {'name': 'Alejandro Alvarez Iorio, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital Privado Sur (FUMEBA)'}, {'name': 'Ignacio J Amat-Santos, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University Clinical Hospital of Valladolid'}, {'name': 'Rimantas Benetis, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Lithuanian University of Health Sciences'}, {'name': 'Pedro Braga, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Unidade Local de Saúde de Gaia e Espinho'}, {'name': 'Juan Horacio A Briales, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital Virgen de la Victoria'}, {'name': 'João Brito, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital de Santa Cruz'}, {'name': 'Duarte Cacela, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital Santa Marta'}, {'name': 'Adriano M Caixeta, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Escola Paulista de Medicina da UNIFESP'}, {'name': 'Praveen Chandra, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Medanta - The Medicity Hospital'}, {'name': 'Christian Dauvergne, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital del Tórax de Santiago'}, {'name': 'Pedro C Ferreira, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital Santa Maria'}, {'name': 'John Jose E, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Christian Medical College Hospital'}, {'name': 'Rony Mathew Kadavil, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Lisie Hospital'}, {'name': 'Gabriel Maluenda, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital Clínico San Borja Arriarán'}, {'name': 'Cesar R Medeiros, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Instituto Nacional de Cardiologia'}, {'name': 'Oscar Mendiz, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Fundación Favaloro'}, {'name': 'Sanjay Mehrotra, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Narayana Health Hospital'}, {'name': 'Marcio J Montenegro Da Costa, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Instituto Estadual de Cardiologia Aloysio de Castro'}, {'name': 'Cesar Morís de La Tassa, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital Universitario Central de Asturias'}, {'name': 'Luis Nombela, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital San Carlos, Madrid'}, {'name': 'Juan Oteo, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital Puerta De Hierro'}, {'name': 'Lino MD Patrício, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital do Espírito Santo de Évora'}, {'name': 'Osvaldo Perez, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital Las Higueras - Talcahuano'}, {'name': 'Ravinder Singh Rao, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'RHL - Rajasthan Hospital'}, {'name': 'Ángel S Recalde, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital Universitario Ramón y Cajal'}, {'name': 'Ander Regueiro, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital Clinic of Barcelona'}, {'name': 'Lluis A Serra, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': "Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau"}, {'name': 'Dimytri Siqueira, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Instituto Dante Pazzanese de Cardiologia'}, {'name': 'Hakan Ucar, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'İ.A.Ü. VM Medical Park Florya Hospital'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'P+F Products + Features GmbH', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Meditrial USA Inc.', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}